| Level/ Typ |
Code |
Anzeigename |
Codesystem |
| 0‑L |
100-8
|
Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
101-6
|
Cefoperazone [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
103-2
|
Ceforanide [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
104-0
|
Ceforanide [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
105-7
|
Ceforanide [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
10653-4
|
Clotrimazole [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
10654-2
|
Clotrimazole [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
10697-1
|
Nystatin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
10698-9
|
Nystatin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
10720-1
|
Terbinafine [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
10721-9
|
Terbinafine [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
107-3
|
Cefotaxime [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
108-1
|
Cefotaxime [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
10868-8
|
Bacitracin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
109-9
|
Cefotaxime [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
121-4
|
Cefpodoxime [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
111-5
|
Cefotetan [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
112-3
|
Cefotetan [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
113-1
|
Cefotetan [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
115-6
|
Cefoxitin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
11575-8
|
Cefmetazole [Susceptibility] by Gradient strip
|
2.16.840.1.113883.6.1 |
| 0‑L |
11576-6
|
Erythromycin+Sulfisoxazole [Susceptibility] by Gradient strip
|
2.16.840.1.113883.6.1 |
| 0‑L |
11577-4
|
Sulfamethoxazole [Susceptibility] by Gradient strip
|
2.16.840.1.113883.6.1 |
| 0‑L |
11578-2
|
Sulfisoxazole [Susceptibility] by Gradient strip
|
2.16.840.1.113883.6.1 |
| 0‑L |
116-4
|
Cefoxitin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
11-7
|
Amikacin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
117-2
|
Cefoxitin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
129-7
|
Cefsulodin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
119-8
|
Cefpodoxime [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
120-6
|
Cefpodoxime [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
123-0
|
Cefprozil [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
124-8
|
Cefprozil [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
12-5
|
Amikacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
125-5
|
Cefprozil [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
138-8
|
Ceftizoxime [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
127-1
|
Cefsulodin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
128-9
|
Cefsulodin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
132-1
|
Ceftazidime [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
13-3
|
Amikacin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
133-9
|
Ceftazidime [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
134-7
|
Ceftazidime [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
136-2
|
Ceftizoxime [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
137-0
|
Ceftizoxime [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
13968-3
|
Penicillin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
140-4
|
Ceftriaxone [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
141-2
|
Ceftriaxone [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
142-0
|
Ceftriaxone [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
14332-1
|
Para aminosalicylate [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
144-6
|
Cefuroxime Parenteral [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
145-3
|
Cefuroxime Parenteral [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
152-9
|
Cephaloglycin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
146-1
|
Cefuroxime Parenteral [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
148-7
|
Cephalexin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
149-5
|
Cephalexin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
150-3
|
Cephalexin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
153-7
|
Cephaloglycin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
154-5
|
Cephaloglycin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
156-0
|
Cephaloridine [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
157-8
|
Cephaloridine [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
15-8
|
Amoxicillin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
158-6
|
Cephaloridine [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
160-2
|
Cephalothin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16099-4
|
Ethionamide [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
161-0
|
Cephalothin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16100-0
|
Rifabutin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
162-8
|
Cephalothin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16387-3
|
Rifabutin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16421-0
|
Azithromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
164-4
|
Cephapirin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
165-1
|
Cephapirin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16-6
|
Amoxicillin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16620-7
|
Clarithromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16623-1
|
Clofazimine [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
166-9
|
Cephapirin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16830-2
|
Erythromycin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
16841-9
|
Ethambutol+Rifampin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
168-5
|
Cephradine [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
173-5
|
Chloramphenicol [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
176-8
|
Chlortetracycline [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
169-3
|
Cephradine [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
170-1
|
Cephradine [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
172-7
|
Chloramphenicol [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
17-4
|
Amoxicillin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
174-3
|
Chloramphenicol [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
177-6
|
Chlortetracycline [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
178-4
|
Chlortetracycline [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
182-6
|
Cinoxacin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
1-8
|
Acyclovir [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
180-0
|
Cinoxacin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
181-8
|
Cinoxacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
18946-4
|
Metronidazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18947-2
|
Mezlocillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18948-0
|
Minocycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18949-8
|
Miocamycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18950-6
|
Moxalactam [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18951-4
|
Nafcillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18952-2
|
Nalidixate [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18953-0
|
Neomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18954-8
|
Netilmicin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18955-5
|
Nitrofurantoin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18956-3
|
Norfloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18957-1
|
Novobiocin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18958-9
|
Nystatin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
184-2
|
Ciprofloxacin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
198-2
|
Cloxacillin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
185-9
|
Ciprofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
186-7
|
Ciprofloxacin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
188-3
|
Clarithromycin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
18855-7
|
5-Fluorocytosine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18857-3
|
Almecillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18859-9
|
Amdinocillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18860-7
|
Amikacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18861-5
|
Amoxicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18862-3
|
Amoxicillin+Clavulanate [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18863-1
|
Amphotericin B [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18864-9
|
Ampicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18865-6
|
Ampicillin+Sulbactam [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18866-4
|
Azithromycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18867-2
|
Azlocillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18868-0
|
Aztreonam [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18869-8
|
Bacampicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18870-6
|
Bacitracin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18871-4
|
Butirosin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18872-2
|
Capreomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18873-0
|
Carbenicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18874-8
|
Cefaclor [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18875-5
|
Cefadroxil [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18876-3
|
Cefamandole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18877-1
|
Cefatrizine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18878-9
|
Cefazolin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18879-7
|
Cefepime [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18880-5
|
Cefixime [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18881-3
|
Cefmetazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18882-1
|
Cefodizime [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18883-9
|
Cefonicid [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18884-7
|
Cefoperazone [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18885-4
|
Ceforanide [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18886-2
|
Cefotaxime [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18887-0
|
Cefotetan [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18888-8
|
Cefoxitin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18889-6
|
Cefpirome [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18890-4
|
Cefpodoxime [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18891-2
|
Cefprozil [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18892-0
|
Cefsulodin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18893-8
|
Ceftazidime [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18894-6
|
Ceftizoxime [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18895-3
|
Ceftriaxone [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18896-1
|
Cefuroxime Parenteral [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18897-9
|
Cephalexin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18898-7
|
Cephaloglycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18899-5
|
Cephaloridine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18900-1
|
Cephalothin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18901-9
|
Cephapirin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18902-7
|
Cephradine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18903-5
|
Chloramphenicol [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18904-3
|
Chlortetracycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18905-0
|
Cinoxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18906-8
|
Ciprofloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18907-6
|
Clarithromycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18908-4
|
Clindamycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18909-2
|
Clotrimazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
189-1
|
Clarithromycin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
18910-0
|
Cloxacillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18911-8
|
Colistimethate
|
2.16.840.1.113883.6.1 |
| 0‑L |
18912-6
|
Colistin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18913-4
|
Cyclacillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18914-2
|
Cycloserine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18915-9
|
Demeclocycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18916-7
|
Dicloxacillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18917-5
|
Doxycycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18918-3
|
Enoxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18919-1
|
Erythromycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18920-9
|
Erythromycin+Sulfisoxazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18921-7
|
Ethambutol [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18922-5
|
Ethionamide [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18923-3
|
Floxacillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18924-1
|
Fluconazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18926-6
|
Framycetin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18927-4
|
Fusidate [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18928-2
|
Gentamicin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18929-0
|
Gentamicin.high potency [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18930-8
|
Gramicidin D [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18931-6
|
Hetacillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18932-4
|
Imipenem [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18934-0
|
Isoniazid [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18935-7
|
Kanamycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18936-5
|
Kanamycin.high potency [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18937-3
|
Ketoconazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18938-1
|
Lincomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18939-9
|
Lomefloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18940-7
|
Loracarbef [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18941-5
|
Lymecycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18942-3
|
Meclocycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18943-1
|
Meropenem [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18944-9
|
Methacycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18945-6
|
Methicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18959-7
|
Ofloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18960-5
|
Oleandomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18961-3
|
Oxacillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18962-1
|
Oxytetracycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18963-9
|
Pefloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18964-7
|
Penicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18965-4
|
Penicillin G [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18966-2
|
Penicillin V [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18967-0
|
Phenethicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18968-8
|
Pipemidate [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18969-6
|
Piperacillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18970-4
|
Piperacillin+Tazobactam [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18971-2
|
Pivampicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18972-0
|
Polymyxin B [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18973-8
|
Pyrazinamide [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18974-6
|
Rifampin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18975-3
|
Ristocetin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18976-1
|
Rolitetracycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18977-9
|
Rosoxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18978-7
|
Roxithromycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18979-5
|
Sisomicin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18980-3
|
Spectinomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18981-1
|
Spiramycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18982-9
|
Streptomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18983-7
|
Streptomycin.high potency [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18984-5
|
Sulfadiazine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18985-2
|
Sulfamethoxazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18986-0
|
Sulfisoxazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18987-8
|
Sulfonamide [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18988-6
|
Talampicillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18989-4
|
Teicoplanin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18990-2
|
Temafloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18991-0
|
Temocillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18992-8
|
Terbinafine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18993-6
|
Tetracycline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18994-4
|
Ticarcillin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18995-1
|
Ticarcillin+Clavulanate [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18996-9
|
Tobramycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18997-7
|
Trimethoprim [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18998-5
|
Trimethoprim+Sulfamethoxazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
18999-3
|
Troleandomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
19-0
|
Amoxicillin+Clavulanate [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
19000-9
|
Vancomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
19001-7
|
Viomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
190-9
|
Clarithromycin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
19149-4
|
Rifabutin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
192-5
|
Clindamycin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
193-3
|
Clindamycin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
194-1
|
Clindamycin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
20375-2
|
Clarithromycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20376-0
|
Clofazimine [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20377-8
|
Ciprofloxacin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20378-6
|
Ceftizoxime [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20379-4
|
Doxycycline [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
196-6
|
Cloxacillin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
197-4
|
Cloxacillin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
200-6
|
Colistimethate by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
201-4
|
Colistimethate by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
202-2
|
Colistimethate by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
20373-7
|
Amikacin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20374-5
|
Ampicillin+Sulbactam [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20380-2
|
Erythromycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20381-0
|
Ethambutol [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20382-8
|
Ethionamide [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20383-6
|
Isoniazid [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20384-4
|
Ofloxacin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20385-1
|
Rifampin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20386-9
|
Rifabutin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20387-7
|
Trimethoprim+Sulfamethoxazole [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20388-5
|
Nitrofurazone [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
20389-3
|
Mupirocin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
20390-1
|
Silver sulfadiazine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
20391-9
|
Mafenide [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
20396-8
|
Levofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
20397-6
|
Sparfloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
20460-2
|
Cefuroxime Oral [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
20461-0
|
Pyrazinamide [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
20462-8
|
Streptomycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
204-8
|
Colistin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
205-5
|
Colistin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
20629-2
|
Levofloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
206-3
|
Colistin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
209-7
|
Cyclacillin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
20-8
|
Amoxicillin+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
208-9
|
Cyclacillin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
210-5
|
Cyclacillin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
21070-8
|
Other Antibiotic [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
212-1
|
Cycloserine [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
21316-5
|
Grepafloxacin [Susceptibility] by Gradient strip
|
2.16.840.1.113883.6.1 |
| 0‑L |
21367-8
|
Levofloxacin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
213-9
|
Cycloserine [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
214-7
|
Cycloserine [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
21-6
|
Amoxicillin+Clavulanate [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
216-2
|
Demeclocycline [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
217-0
|
Demeclocycline [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
23636-4
|
Cefdinir [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23637-2
|
Cefdinir [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
23638-0
|
Grepafloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23639-8
|
Grepafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
23640-6
|
Quinupristin+Dalfopristin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
218-8
|
Demeclocycline [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
220-4
|
Dicloxacillin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
221-2
|
Dicloxacillin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
222-0
|
Dicloxacillin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
225-3
|
Doxycycline [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
224-6
|
Doxycycline [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
226-1
|
Doxycycline [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
228-7
|
Enoxacin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
229-5
|
Enoxacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
230-3
|
Enoxacin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
23-2
|
Amphotericin B [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
232-9
|
Erythromycin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
233-7
|
Erythromycin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
234-5
|
Erythromycin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
236-0
|
Erythromycin+Sulfisoxazole [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
23607-5
|
Capreomycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23608-3
|
Cycloserine [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23609-1
|
Kanamycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23610-9
|
Sparfloxacin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23611-7
|
Para aminosalicylate [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23612-5
|
Azithromycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23613-3
|
Imipenem [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23614-1
|
Trimethoprim [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23615-8
|
Vancomycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23616-6
|
Viomycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
23627-3
|
Clofazimine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23628-1
|
Sparfloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23629-9
|
Para aminosalicylate [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23641-4
|
Quinupristin+Dalfopristin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
23642-2
|
Trovafloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23643-0
|
Trovafloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
23658-8
|
Other Antibiotic [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23659-6
|
Apramycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23709-9
|
Ceftiofur [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23712-3
|
Enrofloxacin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
23740-4
|
Florfenicol [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
24-0
|
Amphotericin B [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
237-8
|
Erythromycin+Sulfisoxazole [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
238-6
|
Erythromycin+Sulfisoxazole [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
23925-1
|
Penicillin [Susceptibility] by Gradient strip
|
2.16.840.1.113883.6.1 |
| 0‑L |
244-4
|
Floxacillin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
240-2
|
Ethambutol [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
241-0
|
Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
242-8
|
Ethambutol [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
245-1
|
Floxacillin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
246-9
|
Floxacillin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
249-3
|
Fluconazole [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
252-7
|
5-Fluorocytosine [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
248-5
|
Fluconazole [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25452-4
|
Itraconazole [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25-7
|
Amphotericin B [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
257-6
|
Framycetin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
250-1
|
Fluconazole [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25174-4
|
Amikacin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25175-1
|
Amikacin 16 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25176-9
|
Amikacin 32 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25177-7
|
Amikacin 12 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25178-5
|
Amikacin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25179-3
|
Amikacin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25180-1
|
Ciprofloxacin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25181-9
|
Ciprofloxacin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25182-7
|
Kanamycin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25183-5
|
Ethionamide 11 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25184-3
|
Rifampin 14 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25185-0
|
Streptomycin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25186-8
|
Pyrazinamide 25 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25187-6
|
Ethambutol 7.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25188-4
|
Ciprofloxacin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25189-2
|
Ciprofloxacin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25190-0
|
Clarithromycin 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25191-8
|
Clarithromycin 16 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25192-6
|
Clarithromycin 32 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25194-2
|
Ethambutol 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25195-9
|
Ethambutol 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25196-7
|
Ethionamide 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25198-3
|
Ethionamide 15 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25199-1
|
Rifabutin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25200-7
|
Rifabutin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25201-5
|
Rifabutin 4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25202-3
|
Rifampin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25203-1
|
Rifampin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25204-9
|
Rifampin 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25205-6
|
Streptomycin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25206-4
|
Streptomycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25207-2
|
Cycloserine 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25208-0
|
Cycloserine 20 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25209-8
|
Cycloserine 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25210-6
|
Capreomycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25211-4
|
Capreomycin 20 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25212-2
|
Capreomycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25213-0
|
Kanamycin 6 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25214-8
|
Kanamycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25215-5
|
Para aminosalicylate 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25216-3
|
Para aminosalicylate 8 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25217-1
|
Isoniazid 0.1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25218-9
|
Isoniazid 0.2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25219-7
|
Isoniazid 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25220-5
|
Cefoxitin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25221-3
|
Imipenem 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25222-1
|
Cefmetazole 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25223-9
|
Doxycycline 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25224-7
|
Erythromycin 15 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25225-4
|
Minocycline 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25226-2
|
Sulfisoxazole 300 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25227-0
|
Tobramycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25228-8
|
Vancomycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25229-6
|
Pyrazinamide 100 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25230-4
|
Ethambutol 2.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25231-2
|
Ethionamide 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25310-4
|
Amoxicillin+Clavulanate [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
253-5
|
5-Fluorocytosine [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25366-6
|
Cefoxitin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25367-4
|
Ceftriaxone [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
25411-0
|
Fleroxacin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
254-3
|
5-Fluorocytosine [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25595-0
|
Econazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
25596-8
|
Fosfomycin [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
25597-6
|
Josamycine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
25607-3
|
Miconazole [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
25608-1
|
Nitroxoline [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
25637-0
|
Econazole [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25653-7
|
Fosfomycin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
256-8
|
Foscarnet [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
25702-2
|
Josamycine [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25722-0
|
Miconazole [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25723-8
|
Nitroxoline [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
25800-4
|
Tobramycin [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
258-4
|
Framycetin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
259-2
|
Framycetin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
2-6
|
Almecillin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
274-1
|
Hetacillin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
261-8
|
Fusidate [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
262-6
|
Fusidate [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
263-4
|
Fusidate [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
265-9
|
Ganciclovir [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
266-7
|
Gentamicin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
267-5
|
Gentamicin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
268-3
|
Gentamicin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
278-2
|
Imipenem [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
270-9
|
Gramicidin D [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
271-7
|
Gramicidin D [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
272-5
|
Gramicidin D [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
27-3
|
Ampicillin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
276-6
|
Hetacillin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
275-8
|
Hetacillin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
279-0
|
Imipenem [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
280-8
|
Imipenem [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
28-1
|
Ampicillin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
286-5
|
Isoniazid [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
287-3
|
Isoniazid [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
288-1
|
Isoniazid [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
290-7
|
Kanamycin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
291-5
|
Kanamycin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
292-3
|
Kanamycin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
29254-0
|
Linezolid [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
29255-7
|
Linezolid [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
29258-1
|
Linezolid [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
29315-9
|
Isoniazid 0.4 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
|
2.16.840.1.113883.6.1 |
| 0‑L |
294-9
|
Ketoconazole [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
296-4
|
Ketoconazole [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
298-0
|
Lincomycin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
295-6
|
Ketoconazole [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
29-9
|
Ampicillin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
299-8
|
Lincomycin [Susceptibility] by Minimum inhibitory concentration (MIC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
300-4
|
Lincomycin [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
302-0
|
Lomefloxacin [Susceptibility] by Minimum lethal concentration (MLC)
|
2.16.840.1.113883.6.1 |
| 0‑L |
308-7
|
Loracarbef [Susceptibility] by Disk diffusion (KB)
|
2.16.840.1.113883.6.1 |
| 0‑L |
30268-7
|
Zidovudine [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30269-5
|
Lamivudine [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30270-3
|
Didanosine [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30271-1
|
Zalcitabine [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30272-9
|
Stavudine [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30273-7
|
Abacavir [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30274-5
|
Adefovir [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30275-2
|
Nevirapine [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30276-0
|
Delavirdine [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30277-8
|
Efavirenz [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30278-6
|
Indinavir [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30279-4
|
Ritonavir [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30280-2
|
Nelfinavir [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30281-0
|
Saquinavir [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30282-8
|
Zidovudine [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30283-6
|
Lamivudine [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30284-4
|
Didanosine [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30285-1
|
Zalcitabine [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30286-9
|
Stavudine [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30287-7
|
Abacavir [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30288-5
|
Adefovir [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30289-3
|
Nevirapine [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30290-1
|
Delavirdine [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30291-9
|
Efavirenz [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30292-7
|
Indinavir [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30293-5
|
Ritonavir [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30294-3
|
Nelfinavir [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30295-0
|
Saquinavir [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30296-8
|
Amprenavir [Susceptibility] by Phenotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30297-6
|
Amprenavir [Susceptibility] by Genotype method
|
2.16.840.1.113883.6.1 |
| 0‑L |
30298-4
|
Lamivudine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
30299-2
|
Amprenavir [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
30300-8
|
Didanosine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
30301-6
|
Zalcitabine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
30302-4
|
Stavudine [Susceptibility]
|
2.16.840.1.113883.6.1 |
| 0‑L |
30303-2
|
Abacavir [Susceptibility]
|
2.16.840.1.113883.6.1 |
| Dieses Value Set beinhaltet 1471 Codes. Um die Publikationsgröße überschaubar zu halten,
wird nur eine Auswahl (500 Codes) des ganzen Sets von Codes gezeigt.
|
|
Value Set ELGA_Antibiotika 2016‑11‑24
Definitiv
